ophthalmology Archives -

Market Access/ News/ News/ News/ Oncology

Roche’s fast-growing eye drug Vabysmo set for EU approval

Phil Taylor Alnylam Pharmaceuticals, Amvuttra, AstraZeneca, Bristol-Myers Squibb, CHMP, Eli Lilly, Eylea, Mounjaro, Opdualag, ophthalmology, Roche, Tezspire, Vabysmo 0 Comment

Roche has been trumpeting the rapid uptake of its new eye disease drug Vabysmo as it takes on

Roche’s fast-growing eye drug Vabysmo set for EU approval

https://pharmaphorum.com/news/roches-fast-growing-eye-drug-vabysmo-set-for-eu-approval/

Events/ Events/ R&D

Ophthalmic Drugs Conference

Nikisha Galoria AI, eyecare, gene therapy, myopia, ophthalmology 0 Comment

Ophthalmic Drugs Conference

https://pharmaphorum.com/events/ophthalmic-drugs-conference-2/

Digital/ News/ News/ News/ Patients

Could an eye test spot people at risk of heart attacks?

Phil Taylor cardiovascular disease, diagnosis, digital health, ophthalmology 0 Comment

An analysis of images of the retina harvested from the UK Biobank resource suggests that it may be

Could an eye test spot people at risk of heart attacks?

https://pharmaphorum.com/news/could-an-eye-test-spot-people-at-risk-of-heart-attacks/

Events/ Events/ R&D

2nd Integrin-Targeted Drug Development Summit

Erin Thomas autoimmune, integrin, ophthalmology, Rare diseases 0 Comment

In collaboration with leading integrin drug developers, including Genentech, 7 Hills Pharma, and Pfizer, the 2nd Integrin-Targeted Drug Development Summit is designed for

2nd Integrin-Targeted Drug Development Summit

https://pharmaphorum.com/events/2nd-integrin-targeted-drug-development-summit/

News/ News/ R&D

Oxurion craters as failed trial cuts its pipeline down to one

Phil Taylor diabetic macular oedema, ophthalmology, Oxurion 0 Comment

Shares in Belgian biotech Oxurion are taking a hammering this morning after it reported that one of its

Oxurion craters as failed trial cuts its pipeline down to one

https://pharmaphorum.com/news/oxurion-craters-as-failed-trial-cuts-its-pipeline-down-to-one/

News/ News/ R&D

Longer-term data raise prospects for Apellis’ pegcetacoplan

Phil Taylor Apellis Pharma, blindness, complement therapeutics, Empaveli, geographic atrophy, ophthalmology, pegcetacoplan 0 Comment

Apellis’ chances of getting regulatory approval for pegcetacoplan, its drug candidate for sight-robbing disease geographic atrophy (GA), may

Longer-term data raise prospects for Apellis’ pegcetacoplan

https://pharmaphorum.com/news/longer-term-data-raise-prospects-for-apellis-pegcetacoplan/

Genetic testing hopes to speed up drug development in rare eye diseases

News/ News/ R&D

Oxurion reports stronger data for diabetic eye disease drug

Phil Taylor Bayer, diabetic macular oedema, Eylea, ophthalmology, Oxurion, Regeneron 0 Comment

Belgian biotech Oxurion has revealed new data from a phase 2 trial of its plasma kallikrein inhibitor THR-149,

Oxurion reports stronger data for diabetic eye disease drug

https://pharmaphorum.com/news/oxurion-reports-stronger-data-for-diabetic-eye-disease-drug/

Market Access/ News/ News

Roche grabs FDA okay for would-be blockbuster eye drug faricimab

Phil Taylor Bayer, DME, Eylea, ophthalmology, Regeneron, regulatory approval, Roche, Susvimo, Vabysmo, wet AMD 0 Comment

The FDA has approved Roche’s much-anticipated faricimab for two major causes of blindness, setting up a market clash

Roche grabs FDA okay for would-be blockbuster eye drug faricimab

https://pharmaphorum.com/news/roche-grabs-fda-okay-for-would-be-blockbuster-eye-drug-faricimab/

News/ News/ Sales and Marketing

AbbVie prices first presbyopia drug Vuity at $80 per month

Phil Taylor AbbVie, Allergan, ophthalmology, presbyopia, pricing, Vuity 0 Comment

AbbVie has ended speculation about what it will charge for its newly-approved Vuity therapy for presbyopia, a sight

AbbVie prices first presbyopia drug Vuity at $80 per month

https://pharmaphorum.com/news/abbvie-prices-first-presbyopia-drug-vuity-at-80-per-month/

Trending

ophthalmology

Login